ANGELA KAY FITCH
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- NEEDHAM, MA
- NPI
- 1811945959
- Received
- $400,693 in 428 records, 2019 to 2025 ($387,243 general, $13,449 research)
- As principal investigator
- $217,665 of research payments to others in 21 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 175 | $182,326 |
| 2024 | General payment | 146 | $121,937 |
| 2024 | Research payment | 4 | $10,988 |
| 2023 | General payment | 66 | $58,744 |
| 2023 | Research payment | 2 | $2,461 |
| 2022 | General payment | 22 | $21,952 |
| 2021 | General payment | 6 | $1,947 |
| 2019 | General payment | 7 | $335 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk Inc | 183 | $168,823 | 2019–2025 |
| Lilly USA, LLC | 157 | $117,523 | 2023–2025 |
| Currax Pharmaceuticals LLC | 34 | $51,191 | 2024–2025 |
| Eli Lilly and Company | 16 | $31,378 | 2022–2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 23 | $16,885 | 2025 |
| Rhythm Pharmaceuticals, Inc. | 4 | $5,607 | 2024–2025 |
| VIVUS LLC | 2 | $2,862 | 2022 |
| Novo Nordisk AS | 1 | $2,812 | 2023 |
| ABBVIE INC. | 2 | $2,530 | 2025 |
| PFIZER INC. | 1 | $900 | 2025 |
| SCYNEXIS, Inc. | 1 | $92 | 2022 |
| Amgen Inc. | 2 | $40 | 2024–2025 |
| Madrigal Pharmaceuticals | 1 | $25 | 2024 |
| Abbott Laboratories | 1 | $21 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 127 | $212,073 |
| Consulting Fee | 44 | $103,101 |
| Travel and Lodging | 105 | $56,229 |
| Research payment | 6 | $13,449 |
| Food and Beverage | 142 | $11,081 |
| Honoraria | 4 | $4,757 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | PFIZER INC. | $900 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,150 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $140 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,037 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-24 | Currax Pharmaceuticals LLC | $4,500 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2025 | |
| 2025-11-20 | Eli Lilly and Company | $1,925 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | Eli Lilly and Company | $1,925 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Novo Nordisk Inc | $1,627 | Consulting Fee | Cash or cash equivalent | Drug, Multiple Therapeutic Areas | 2025 | |
| 2025-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $90 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-12 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-12 | Lilly USA, LLC | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $307 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-07 | Currax Pharmaceuticals LLC | $1,624 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-11-06 | Currax Pharmaceuticals LLC | $229 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-11-06 | Currax Pharmaceuticals LLC | $133 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,660 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-02 | Currax Pharmaceuticals LLC | $230 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $398 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-16 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-08 | Novo Nordisk Inc | $2,092 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-08 | Novo Nordisk Inc | $102 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-12 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-12 | Lilly USA, LLC | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-05 | Currax Pharmaceuticals LLC | $1,145 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-09-05 | Currax Pharmaceuticals LLC | $566 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $415 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $190 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-28 | Currax Pharmaceuticals LLC | $925 | Honoraria | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-08-26 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-26 | Lilly USA, LLC | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-21 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-21 | Lilly USA, LLC | $390 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-21 | Lilly USA, LLC | $314 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-21 | Lilly USA, LLC | $292 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-21 | Lilly USA, LLC | $115 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-13 | Currax Pharmaceuticals LLC | $4,800 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2025 | |
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,055 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $140 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-11 | Novo Nordisk Inc | $6,161 | Consulting Fee | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $963 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $453 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $281 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $216 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-06 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-06 | Lilly USA, LLC | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-04 | Lilly USA, LLC | $449 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | Currax Pharmaceuticals LLC | $464 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-08-01 | Currax Pharmaceuticals LLC | $59 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-08-01 | Currax Pharmaceuticals LLC | $13 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-07-30 | Rhythm Pharmaceuticals, Inc. | $1,596 | Honoraria | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | Rhythm Pharmaceuticals, Inc. | $1,596 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Lilly USA, LLC | $825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $142 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $54 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-15 | Lilly USA, LLC | $88 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $136 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $477 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-25 | Novo Nordisk Inc | $930 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Novo Nordisk Inc | $691 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-06-22 | Novo Nordisk Inc | $5,463 | Consulting Fee | Cash or cash equivalent | Saxenda Drug, Obesity | 2025 | |
| 2025-06-22 | Novo Nordisk Inc | $2,145 | Travel and Lodging | In-kind items and services | Saxenda Drug, Obesity | 2025 | |
| 2025-06-22 | Novo Nordisk Inc | $771 | Travel and Lodging | In-kind items and services | Saxenda Drug, Obesity | 2025 | |
| 2025-06-22 | Novo Nordisk Inc | $380 | Travel and Lodging | In-kind items and services | Saxenda Drug, Obesity | 2025 | |
| 2025-06-22 | Novo Nordisk Inc | $77 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2025 | |
| 2025-06-21 | Novo Nordisk Inc | $40 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-21 | Currax Pharmaceuticals LLC | $16 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-06-17 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-06-10 | ABBVIE INC. | $550 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-05 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-06-05 | Lilly USA, LLC | $825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-05-29 | Novo Nordisk Inc | $92 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-05-28 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-05-28 | Lilly USA, LLC | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-05-22 | Novo Nordisk Inc | $2,092 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-05-22 | Lilly USA, LLC | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-05-22 | Novo Nordisk Inc | $107 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-05-21 | Lilly USA, LLC | $888 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-21 | Lilly USA, LLC | $93 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-05-14 | Currax Pharmaceuticals LLC | $1,138 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-05-11 | Currax Pharmaceuticals LLC | $113 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-05-08 | Currax Pharmaceuticals LLC | $11,222 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-05-08 | Currax Pharmaceuticals LLC | $4,500 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2025 | |
| 2025-05-06 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-30 | Currax Pharmaceuticals LLC | $856 | Honoraria | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-04-26 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-10 | Lilly USA, LLC | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-08 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-07 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-01 | Novo Nordisk Inc | $930 | Consulting Fee | Cash or cash equivalent | Saxenda Drug, Obesity | 2025 | |
| 2025-03-27 | Novo Nordisk Inc | $2,673 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-27 | Novo Nordisk Inc | $752 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-27 | Novo Nordisk Inc | $114 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-27 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-22 | Novo Nordisk Inc | $5,928 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-22 | Novo Nordisk Inc | $379 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-22 | Novo Nordisk Inc | $138 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-22 | Novo Nordisk Inc | $124 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-22 | Novo Nordisk Inc | $54 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-22 | Novo Nordisk Inc | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-21 | Novo Nordisk Inc | $4,998 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-21 | Novo Nordisk Inc | $379 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-21 | Novo Nordisk Inc | $350 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-21 | Novo Nordisk Inc | $294 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-21 | Novo Nordisk Inc | $72 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-21 | Novo Nordisk Inc | $42 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-20 | Novo Nordisk Inc | $4,766 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-20 | Novo Nordisk Inc | $960 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-20 | Novo Nordisk Inc | $124 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-17 | Eli Lilly and Company | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-17 | Eli Lilly and Company | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-17 | Lilly USA, LLC | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-03-13 | Lilly USA, LLC | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-03-13 | Lilly USA, LLC | $825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-03-12 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-11 | Eli Lilly and Company | $620 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-11 | Eli Lilly and Company | $345 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-11 | Lilly USA, LLC | $135 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-11 | Lilly USA, LLC | $123 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-03-10 | Lilly USA, LLC | $124 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-03-08 | Novo Nordisk Inc | $1,860 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-06 | Novo Nordisk Inc | $4,068 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-03-06 | Novo Nordisk Inc | $805 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-06 | Novo Nordisk Inc | $77 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-03-05 | Currax Pharmaceuticals LLC | $1,500 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2025 | |
| 2025-02-25 | Currax Pharmaceuticals LLC | $145 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-02-17 | Novo Nordisk Inc | $2,790 | Consulting Fee | Cash or cash equivalent | Saxenda Drug, Obesity | 2025 | |
| 2025-02-17 | Novo Nordisk Inc | $930 | Consulting Fee | Cash or cash equivalent | Saxenda Drug, Obesity | 2025 | |
| 2025-02-10 | Lilly USA, LLC | $170 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-02-10 | Lilly USA, LLC | $108 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-02-10 | Lilly USA, LLC | $39 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-02-10 | Lilly USA, LLC | $24 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-31 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-31 | Lilly USA, LLC | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-31 | Lilly USA, LLC | $217 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-31 | Lilly USA, LLC | $175 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-30 | Lilly USA, LLC | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-28 | Lilly USA, LLC | $241 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-28 | Lilly USA, LLC | $211 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-28 | Lilly USA, LLC | $180 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Lilly USA, LLC | $2,031 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $545 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $253 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $253 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $253 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $253 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $197 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Lilly USA, LLC | $121 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Lilly USA, LLC | $115 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $70 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Lilly USA, LLC | $60 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $55 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $39 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $39 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $39 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $39 | Travel and Lodging | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $35 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $35 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-22 | Lilly USA, LLC | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-01-10 | ABBVIE INC. | $1,980 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-01-01 | Novo Nordisk Inc | $1,185 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2024-12-10 | Novo Nordisk Inc | $15 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-12-05 | Novo Nordisk Inc | $938 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2024 | |
| 2024-12-03 | Novo Nordisk Inc | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | Currax Pharmaceuticals LLC | $2,375 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-18 | Lilly USA, LLC | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2024 | |
| 2024-11-13 | Currax Pharmaceuticals LLC | $3,000 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-08 | Currax Pharmaceuticals LLC | $4,500 | Consulting Fee | Cash or cash equivalent | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-06 | Currax Pharmaceuticals LLC | $618 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-06 | Currax Pharmaceuticals LLC | $162 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-06 | Madrigal Pharmaceuticals | $25 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-11-05 | Currax Pharmaceuticals LLC | $120 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-05 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-03 | Novo Nordisk Inc | $105 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | Currax Pharmaceuticals LLC | $501 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-11-02 | Currax Pharmaceuticals LLC | $189 | Travel and Lodging | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-10-16 | Novo Nordisk Inc | $1,687 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2024 | |
| 2024-10-16 | Novo Nordisk Inc | $103 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-15 | Novo Nordisk Inc | $143 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-14 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-09 | Currax Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2024 | |
| 2024-10-03 | Novo Nordisk Inc | $2,437 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2024 | |
| 2024-10-03 | Novo Nordisk Inc | $102 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-01 | Novo Nordisk Inc | $1,687 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2024 | |
| 2024-10-01 | Novo Nordisk Inc | $103 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-09-26 | Eli Lilly and Company | $2,250 | Consulting Fee | Cash or cash equivalent | 2024 |
The latest 200 records of 428.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-03-11 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $8,091 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN A | 2025 |
| 2025-02-04 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $55,718 | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE L | 2025 |
| 2025-01-31 | Eli Lilly and Company | KNOWNWELL | $4,222 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2025 |
| 2025-01-30 | Eli Lilly and Company | KNOWNWELL | $2,035 | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE L | 2025 |
| 2025-01-19 | Eli Lilly and Company | KNOWNWELL | $3,230 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2025-01-09 | Eli Lilly and Company | KNOWNWELL | $1,634 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN A | 2025 |
| 2025-01-09 | Eli Lilly and Company | KNOWNWELL | $888 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2025-01-09 | Eli Lilly and Company | KNOWNWELL | $5,975 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2025 |
| 2025-01-07 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $13,349 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2025 |
| 2025-01-07 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $27,525 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2024-10-16 | Eli Lilly and Company | KNOWNWELL | $513 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2024 |
| 2024-09-15 | Eli Lilly and Company | KNOWNWELL | $3,200 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2024 |
| 2024-08-27 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $45,536 | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE L | 2024 |
| 2024-08-20 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $15,000 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2024 |
| 2024-08-20 | Eli Lilly and Company | SEEN MEDICAL OF MA PC DBA KNOWNWELL | $22,041 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN A | 2024 |
| 2024-08-08 | Eli Lilly and Company | KNOWNWELL | $997 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2024 |
| 2024-08-08 | Eli Lilly and Company | KNOWNWELL | $1,362 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN A | 2024 |
| 2024-07-09 | Eli Lilly and Company | KNOWNWELL | $4,048 | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE L | 2024 |
| 2021-03-25 | Boehringer Ingelheim France S.A.S. | Massachusetts General Hospital | $1,600 | Ph IIb dose finding vs placebo in patients with Obesity | 2021 |
| 2021-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Massachusetts General Hospital | $520 | Ph IIb dose finding vs placebo in patients with Ob | 2021 |
| 2021-03-03 | Boehringer Ingelheim France S.A.S. | Massachusetts General Hospital | $177 | Ph IIb dose finding vs placebo in patients with Obesity | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Needham, MA, county Norfolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Needham, MA | County Norfolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 32,459 | 730,082 | 7,044,056 |
| Population, 2020 census P1 | 32,091 | 725,981 | 7,029,917 |
| Median age B01002 | 43.1 | 40.9 | 40.0 |
| Under 18 B01001 | 27.5% | 20.5% | 19.4% |
| 65 and over B01001 | 17.7% | 17.8% | 17.9% |
| Households B11001 | 11,586 | 283,368 | 2,785,042 |
| Foreign born B05002 | 16.8% | 19.3% | 18.0% |
| Median household income B19013 | $214,308 | $130,739 | $103,960 |
| Median family income B19113 | $250,001 | $170,406 | $131,675 |
| Per capita income B19301 | $102,328 | $71,758 | $57,897 |
| Poverty rate B17001 | 3.7% | 6.7% | 10.0% |
| Unemployment rate B23025 | 4.4% | 4.9% | 5.2% |
| Civilian labor force B23025 | 16,759 | 414,608 | 3,911,446 |
| Mean commute (minutes) B08013 | 27.7 | 32.5 | 29.1 |
| Bachelor's degree or higher B15003 | 81.9% | 58.8% | 47.3% |
| Housing units B25001 | 11,929 | 295,227 | 3,030,406 |
| Owner-occupied B25003 | 83.1% | 68.7% | 62.5% |
| Renters B25003 | 16.9% | 31.3% | 37.5% |
| Median home value B25077 | $1,188,500 | $683,900 | $562,100 |
| Median gross rent B25064 | $2,409 | $2,149 | $1,762 |
| White, not Hispanic B03002 | 80.8% | 68.7% | 66.6% |
| Black B03002 | 1.5% | 7.1% | 6.4% |
| Hispanic or Latino B03002 | 3.6% | 5.8% | 13.3% |
| Asian B03002 | 9.9% | 12.4% | 7.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Needham, MA.
Comments